The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
Comments on the effect of algorithms and artificial intelligence on the likelihood of coordinated effects as described in Guideline 3 of the draft Merger Guidelines
In this note, we discuss how the Antitrust Division of the Department of Justice and the Federal Trade Commission (collectively, the Agencies) view the effect...